Mydecine Innovations Group Inc
Noveris Health Sciences Inc., a biotechnology company, engages in the research, development, and commercialization of psilocybin products to treat mental health conditions. The company primarily focuses on treating nicotine addiction and post-traumatic stress disorder. It also develops MYCO-005, MYCO-006, and MYCO-007 for MDMA and psilocybin analogs. The company has a partnership with Applied Pha… Read more
Mydecine Innovations Group Inc (MYCOF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.003x
Based on the latest financial reports, Mydecine Innovations Group Inc (MYCOF) has a cash flow conversion efficiency ratio of -0.003x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($46.85K) by net assets ($-15.16 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Mydecine Innovations Group Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Mydecine Innovations Group Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Mydecine Innovations Group Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mydecine Innovations Group Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sound Point Meridian Capital, Inc.
PINK:SPMA
|
-0.328x |
|
Orlen SA
PR:ORLEN
|
N/A |
|
Kure Technologies Inc
OTCGREY:UBSBF
|
0.010x |
|
Resolute Resources Ltd.
V:RRL
|
N/A |
|
GAS NATURAL SDG - Dusseldorf Stock Exchang
DU:GAN
|
0.043x |
|
Handeni Gold Inc
PINK:HNDI
|
0.097x |
|
Bentley Capital Ltd
AU:BEL
|
-0.088x |
|
INTSIG ORD A (SHH) EQSW Exp:
SHG:688615
|
N/A |
Annual Cash Flow Conversion Efficiency for Mydecine Innovations Group Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Mydecine Innovations Group Inc from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-14.92 Million | $-37.32K | 0.003x | -99.29% |
| 2023-12-31 | $-11.92 Million | $-4.22 Million | 0.354x | -84.88% |
| 2022-12-31 | $-3.60 Million | $-8.43 Million | 2.341x | +102.06% |
| 2021-12-31 | $211.32K | $-24.05 Million | -113.821x | -5588.73% |
| 2020-12-31 | $3.56 Million | $-7.12 Million | -2.001x | -1251.30% |
| 2019-12-31 | $10.04 Million | $-1.49 Million | -0.148x | +87.50% |
| 2018-12-31 | $3.36 Million | $-3.99 Million | -1.185x | +71.99% |
| 2017-12-31 | $1.25 Million | $-5.30 Million | -4.230x | -282.00% |
| 2016-12-31 | $1.33 Million | $-1.47 Million | -1.107x | -119.74% |
| 2015-12-31 | $-151.94K | $-852.46K | 5.611x | +575.68% |
| 2014-12-31 | $92.75K | $-109.40K | -1.179x | -23563.81% |
| 2013-12-31 | $935.18K | $4.70K | 0.005x | -91.18% |
| 2012-12-31 | $-1.04 Million | $-59.16K | 0.057x | -- |